Purpose Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%. current users. For ladies with up to one 12 months of tamoxifen use the odds ratio for contralateral breast malignancy was 0.37 (95% CI: 0.20 – 0.69; p = 0.001) compared to women with no tamoxifen… Continue reading Purpose Women with a mutation in BRCA1 or BRCA2 face a